S&P's Top Biotech Beneficiaries of Health Care Reform

Updated

With the passage of the U.S. Senate's version of the health care reform bill on Christmas Eve, investors may now want to take a look at the growth prospects for the biotech industry. It's likely to benefit from the legislation that's leading to a major health care industry overhaul in 2010.

Advertisement